NCT04294576: Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors

NCT04294576
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Phase 1a
Exclusions: Patients with uncontrolled CNS metastases
https://ClinicalTrials.gov/show/NCT04294576

Comments are closed.

Up ↑